CO6210734A2 - Conjugados de anticuerpo anti-rg-1 - Google Patents

Conjugados de anticuerpo anti-rg-1

Info

Publication number
CO6210734A2
CO6210734A2 CO10064681A CO10064681A CO6210734A2 CO 6210734 A2 CO6210734 A2 CO 6210734A2 CO 10064681 A CO10064681 A CO 10064681A CO 10064681 A CO10064681 A CO 10064681A CO 6210734 A2 CO6210734 A2 CO 6210734A2
Authority
CO
Colombia
Prior art keywords
seq
chain variable
variable region
antibody
heavy chain
Prior art date
Application number
CO10064681A
Other languages
English (en)
Spanish (es)
Inventor
David J King
Jonathan Terrett
Sanjeev Gangwar
Josephine M Cardarelli
Chetana Rao-Naik
Chin Pan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6210734(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO6210734A2 publication Critical patent/CO6210734A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO10064681A 2007-11-30 2010-05-28 Conjugados de anticuerpo anti-rg-1 CO6210734A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99169007P 2007-11-30 2007-11-30

Publications (1)

Publication Number Publication Date
CO6210734A2 true CO6210734A2 (es) 2010-10-20

Family

ID=40427118

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10064681A CO6210734A2 (es) 2007-11-30 2010-05-28 Conjugados de anticuerpo anti-rg-1

Country Status (18)

Country Link
US (1) US20110020329A1 (ko)
EP (1) EP2211908A2 (ko)
JP (1) JP2011505371A (ko)
KR (1) KR20100101122A (ko)
CN (1) CN101951960A (ko)
AR (1) AR069746A1 (ko)
AU (1) AU2008331507A1 (ko)
BR (1) BRPI0819765A2 (ko)
CA (1) CA2707443A1 (ko)
CL (1) CL2008003525A1 (ko)
CO (1) CO6210734A2 (ko)
EA (1) EA201000921A1 (ko)
IL (1) IL206060A0 (ko)
MX (1) MX2010005683A (ko)
NZ (1) NZ586514A (ko)
TW (1) TW200930407A (ko)
WO (1) WO2009073524A2 (ko)
ZA (1) ZA201003729B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518403B2 (en) * 2004-07-16 2013-08-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
NO2344478T3 (ko) 2008-11-03 2018-02-24
DK3056203T3 (da) 2010-04-21 2018-01-29 Syntarga Bv Konjugater af cc-1065-analoger og bifunktionelle linkere.
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
JP6320753B2 (ja) 2010-05-27 2018-05-09 ゲンマブ エー／エス Ｈｅｒ２に対するモノクローナル抗体
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US10266606B2 (en) 2014-01-10 2019-04-23 Synthon Biopharmaceuticals B.V. Method for purifying Cys-linked antibody-drug conjugates
CA2937561A1 (en) * 2014-01-29 2015-08-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
MX2020001270A (es) 2017-07-31 2020-09-22 Trishula Therapeutics Inc Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978757A (en) * 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
EP0527189A1 (en) * 1990-04-25 1993-02-17 PHARMACIA & UPJOHN COMPANY Novel cc-1065 analogs
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2165819C (en) * 1994-04-22 2005-12-27 Nobuyoshi Amishiro Dc-89 derivatives
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
EP2266986A1 (en) * 2001-05-31 2010-12-29 Medarex, Inc. Cytotoxins, Prodrugs, Linkers and Stabilizers useful therefor
WO2003022806A2 (en) * 2001-09-07 2003-03-20 The Scripps Research Institute Cbi analogues of cc-1065 and the duocarmycins
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
KR101215218B1 (ko) * 2003-07-22 2012-12-26 바이엘 파마 악티엔게젤샤프트 Ｒｇ１ 항체 및 그의 용도
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP1747021B1 (en) * 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP1940470B1 (en) * 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
WO2007059404A2 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
JP5189082B2 (ja) * 2006-05-25 2013-04-24 バイエル・ファルマ・アクチェンゲゼルシャフト 二量体分子複合体

Also Published As

Publication number Publication date
EP2211908A2 (en) 2010-08-04
EA201000921A1 (ru) 2010-12-30
AR069746A1 (es) 2010-02-17
TW200930407A (en) 2009-07-16
MX2010005683A (es) 2010-06-11
WO2009073524A3 (en) 2009-12-10
US20110020329A1 (en) 2011-01-27
CA2707443A1 (en) 2009-06-11
ZA201003729B (en) 2011-08-31
IL206060A0 (en) 2010-11-30
AU2008331507A1 (en) 2009-06-11
JP2011505371A (ja) 2011-02-24
CL2008003525A1 (es) 2010-01-22
NZ586514A (en) 2012-05-25
KR20100101122A (ko) 2010-09-16
WO2009073524A2 (en) 2009-06-11
BRPI0819765A2 (pt) 2015-05-05
CN101951960A (zh) 2011-01-19

Similar Documents

Publication Publication Date Title
CO6210734A2 (es) Conjugados de anticuerpo anti-rg-1
AR050642A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
AR064109A1 (es) Anticuerpos humanos que se enlazan al cd22 y sus usos
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
AR091605A1 (es) Proteinas de union anti-mesotelina
CO6290705A2 (es) Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
WO2019215510A8 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
WO2011159847A3 (en) Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
NI200900005A (es) Anticuerpo antagonista para el tratamiento del cáncer
CR20200459A (es) Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
AR080513A1 (es) Moleculas de union cd37 y sus inmunoconjugados
CR10656A (es) Proteinas de union a interleuquina-13
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
ATE505544T1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
ECSP12011761A (es) Moléculas de anticuerpo anti-gcc y composiciones y métodos relacionados.
PE20090368A1 (es) Anticuerpos anti-igf
IN2009KN02404A (ko)
UA116874C2 (uk) Імунокон'югат анти-мезотеліну

Legal Events

Date Code Title Description
FC Application refused